一、核心观点与数据更新本报告主要围绕Akeso(9926HK)的全球HARMONi试验数据展开分析,特别是AK112联合化疗在二线治疗3代EGFR-TKI耐药非小细胞肺癌(NSCLC)中的表现。数据显示,在更长的随访中,总生存期(OS)有所改善,但西方患者的无进展生存期(PFS)和OS的风险比(HR)略逊于中国患者。研究者认为,这种差异可能部分归因于西方患者随访时间较短,尤其是欧洲患者。尽管最终...
Source Link一、核心观点与数据更新本报告主要围绕Akeso(9926HK)的全球HARMONi试验数据展开分析,特别是AK112联合化疗在二线治疗3代EGFR-TKI耐药非小细胞肺癌(NSCLC)中的表现。数据显示,在更长的随访中,总生存期(OS)有所改善,但西方患者的无进展生存期(PFS)和OS的风险比(HR)略逊于中国患者。研究者认为,这种差异可能部分归因于西方患者随访时间较短,尤其是欧洲患者。尽管最终...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.